USE OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS SG105 TO DELAY AGING

Abstract

USE OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS SG105 FOR DELAYING AGING The invention relates to a use of Bifidobacterium animalis subsp. lactis SG105 for delaying aging. Administering an effective amount of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual can reduce the amount of peroxides, and thus oxidative stress, in the individual's body to prevent oxidative damage to cells or tissues, thereby producing an anti-aging effect and delaying diseases or symptoms caused by aging.

Description

Title of the invention: USE OF BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS SG105 FOR DELAYING AGING BACKGROUND OF THE INVENTION

[0001] 1. Technical field

[0002] The present invention relates to a second use of a probiotic strain. More particularly, the invention relates to a use of Bifidobacterium animalis subsp. lactis SG105 for delaying aging.

[0003] 2. Description of the related art

[0004] Improvements in medical care and quality of life have led to an increase in the average life expectancy of human beings every year; as a result, the elderly population continues to increase worldwide. According to statistics, people aged 65 and over in 2022 accounted for 10% of the world's population that year, and the United Nations has predicted that this percentage will reach 16% by 2050. Considering the effects of aging on human health and social welfare systems, the question of how to delay aging has not only become an important issue in all countries, but is also an issue that can create business opportunities, among others in the pharmaceutical industry, the biotechnology industry, the cosmetics and body care industry, and the health food industry.

[0005] Research data has shown that the global anti-aging products market is expected to reach $93.1 billion by 2027, with nutritional supplements and health foods holding the largest share, followed by the treatment and prevention of age-related diseases. With the biotechnology and medical industries now focusing on the development of anti-aging products and technologies, it is important for every relevant manufacturer to find ways to produce effective and safe anti-aging products. BRIEF SUMMARY OF THE INVENTION

[0006] The main objective of the present invention is to provide a use of Bifidobacterium animalis subsp. lactis SG105 for delaying aging such that the administration of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual effectively contributes to maintaining the individual's figure, memory and physical appearance.

[0007] The secondary objective of the present invention is to provide a use of Bifi- Bifido-bacterium animalis subsp. lactis SG105 to delay aging, Bifido-bacterium animalis subsp. lactis SG105 being a probiotic strain with anti-aging activity and having no side effects on an individual and also not causing substance addiction after long-term consumption.

[0008] To achieve the above-mentioned objectives, the present invention discloses a use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of an anti-aging and / or antioxidant composition, wherein Bifidobacterium animalis subsp. lactis SG105 has been deposited with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the deposit number being DSM 34662 and the filing date being June 8, 2023.

[0009] The anti-aging composition may be a food product, a nutritional supplement, a drug or a body care product.

[0010] The present invention also discloses a use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of a composition for memory enhancement, wherein Bifidobacterium animalis subsp. lactis SG105 has been deposited with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the deposit number being DSM 34662 and the filing date being June 8, 2023. The composition for memory enhancement may be a food product, a nutritional supplement, or a medicament.

[0011] The composition according to the invention may be a food, a body care product for external use, a nutritional supplement or a medicament. The composition may be prepared in different dosage forms, such as drops, powder, tablets and capsules, depending on the persons to whom the composition will be administered, the method of administration and the method of consumption. The composition may also comprise additional ingredients such as an excipient, a sweetener and a vehicle.

[0012] When prepared as a nutritional supplement, the composition comprises an effective amount of Bifidobacterium animalis subsp. lactis SG105 and a food-acceptable ingredient. When prepared as a medicament, the composition comprises an effective amount of Bifidobacterium animalis subsp. lactis SG105 and a pharmaceutically acceptable carrier.

[0013] Bifidobacterium animalis subsp. lactis SG105 is effective in enhancing the activity of anti-oxidation-related enzymes (e.g., superoxide dismutase and catalase) in an individual's body. Therefore, when administered to an individual, the aforementioned composition can effectively eliminate or reduce the amount of peroxides in the individual's body in order to prevent cells from being damaged by oxidative stress, thereby delaying the individual's aging and, consequently, the individual's aging-related diseases and symptoms. In other words, the composition described herein can be used to resist aging, delay memory loss, improve learning abilities, reduce cellular damage, maintain an individual's physical appearance, and prevent them from appearing old.

[0014] BRIEF DESCRIPTION OF THE DIFFERENT VIEWS OF THE FIGURES

[0015] [Fig.l] shows the result of evaluating the aging index of mice of each group in Example 2.

[0016] [Fig.2] shows the result of the single-trial passive avoidance test of mice in each group at the 24th hour following learning and training.

[0017] [Fig.3] shows the result of the active avoidance test of mice in each group. second day of the test.

[0018] [Fig.4] shows the analysis result of superoxide dismutase activity in the liver of mice in each group.

[0019] [Fig.5] shows the result of analysis of catalase activity in the liver of mice in each group. DETAILED DESCRIPTION OF THE INVENTION

[0020] The present invention discloses a use of Bifidobacterium animalis subsp. lactis SG105 for delaying aging. Since Bifidobacterium animalis subsp. lactis SG105 can increase the activity of superoxide dismutase and catalase, administering an effective amount of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual can reduce the amount of peroxides, and thus oxidative stress, in the individual's body to prevent oxidative damage to cells or tissues, thereby producing an anti-aging effect and delaying diseases or symptoms caused by aging, such as memory loss, reduced learning ability, and an aged physical appearance.

[0021] Bifidobacterium animalis subsp. lactis SG105 has been deposited with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ). The deposit number is DSM 34662 and the deposit date is June 8, 2023.

[0022] The term "administering" refers to giving a substance such as a drug to an individual. The method of administration is not limited to oral administration, and it is possible to administer a substance or drug at the same time as a common food or food composition is provided to be consumed.

[0023] The term "composition" means a substance such as a food product, nutritional supplement or animal feed which contains Bifidobacterium animalis subsp. lactis SG105 as the main active ingredient, and which can be prepared in various dosage forms such as powder, tablets, liquid and capsules, depending on the individuals to whom the composition will be administered, the dosage of administration and the method of administration.

[0024] The term "effective amount" or "effective dose" refers to a dose that achieves the intended effect of the present invention in an individual, the dose being able to vary depending on the individual to whom the substance in question is administered.

[0025] The term "aging" refers to changes in the physiological conditions, body or physical appearance of an individual due to increasing age, such as wrinkles, decreased vigor, memory loss, increased spinal curvature, swelling of the eyelids, tendency to fatigue, coarse hair, hair loss, skin ulcers, decreased hair shine and reduced anti-oxidation capacity.

[0026] The terms "anti-aging" or "resisting aging" refer to reducing the rate of aging or the appearance of aging-related symptoms, or improving or enhancing the condition of an individual's body or physical appearance after it has been impaired by aging.

[0027] The technical characteristics of the present invention and their intended effects are detailed below with reference to examples and the attached drawings.

[0028] The Bifidobacterium animalis subsp. lactis SG105 used in the following examples has been deposited with the German Collection of Microorganisms and Cell Cultures GmbH. The deposit number is DSM 34662 and the deposit date is June 8, 2023.

[0029] The animals used in the following examples are SAMP8 mice. This mouse strain has a short lifespan and has been recognized in the technical field to which the present invention relates as an experimental animal model suitable for use in studies relating to the delay of aging and reproductive functions.

[0030] The single-trial passive avoidance test and the active avoidance test described in the following examples are methods commonly used in the technical field to which the present invention relates for testing the learning ability and memory of an individual.

[0031] Example 1: Preparation of a probiotic sample

[0032] Bifidobacterium animalis subsp. lactis SG105 was cultured and propagated in a liquid carbon and nitrogen-based culture medium to produce a liquid bacterial, from which a bacterial sludge was then separated by centrifugation. The bacterial sludge was subjected to preparation processes such as freeze-drying and grinding, and a sample of Bifidobacterium animalis subsp. lactis SG105 was obtained as a result. Example 2: Animal Testing

[0033] Several three-month-old SAMP8 mice were randomly divided into two groups, one being the control group as a reference for comparison between the aging states of the two groups, and the other being the Bifidobacterium animalis subsp. lactis SG105 group. The control group was tube-fed with double-distilled water (ddH2O), and the Bifidobacterium animalis subsp. lactis SG105 group with the sample of Bifidobacterium animalis subsp. lactis SG105 (1x109 colony-forming units (CFU) / mouse / day), with tube-feeding performed once a day. Other rearing conditions of the two groups were the same. The test lasted for 13 weeks, during which not only were the body weight of the mice and the amounts of food and water consumed recorded, but also predetermined aging indices were evaluated.

[0034] Example 3: Results of the evaluation of the aging indices of mice

[0035] The following aspects of physical appearance, eye condition and deviation of The spine of mice in each group were evaluated by observation and touch: hair gloss, hair hardness, hair loss, skin ulcer, mucus around the eyes or periophthalmic lesion, and lordosis / kyphosis of the spine (examined by visual inspection and touch). The evaluation result of each aspect was classified into five levels and given a score of 0, 1, 2, 3, or 4, where the higher the score, the more severe the aging phenomenon. The scores of all aspects were summed and the average was calculated for each group, and the results are shown in [Fig.l].

[0036] According to the results of [Fig.l], the average of the summed scores of the aging indices of the Bifidobacterium animalis subsp. lactis SG105 group is 3.63 ± 0.24, which is significantly lower than that of the control group (6.25 ± 0.55). This indicates that Bifidobacterium animalis subsp. lactis SG105 is capable of suppressing the manifestation of aging; in other words, administering an effective amount of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual can produce an anti-aging effect or help resist the symptoms of aging.

[0037] Example 4: Single-Trial Passive Avoidance Test

[0038] A 35 (Width)^ 17 (Depth)^ 20 (Height) cm3 aluminum shuttle avoidance cage (Coulboum Instruments, Model E10-15) was used for the test. The lower part of the aluminum shuttle avoidance cage was equipped with ge metal shock absorbers arranged in parallel, and the cage was divided into two compartments by an aluminum plate in the center. The aluminum plate was fitted with an automatic guillotine door of 7.5 (Width)^ 6.5 (Depth) cm2 (Coulbourn Instruments, model E10-15GD). One of the two compartments was illuminated to form a lighted compartment. The other compartment was not illuminated and was covered with black cover plates to form a dark compartment.

[0039] The test was conducted as follows. With the guillotine door closed, a mouse was placed in the lighted compartment. After 10 seconds, the guillotine door was automatically opened so that the mouse could move freely between compartments. Once the mouse entered the dark compartment, the guillotine door was closed, and 5 seconds later, the mouse received three consecutive electric shocks of 0.5 pA at an interval of 5 seconds, each electric shock lasting 0.5 seconds. If the mouse did not enter the dark compartment within 180 seconds, the test was automatically terminated. The first day was used for learning and training, and therefore the electric shocks were administered as established above. After learning and training, no electric shocks were administered.The test continued until the 24th hour after learning and training, and during this hour, the time the mice in each group remained in the illuminated compartment (i.e., the latency time) was recorded, as shown in [Fig.2].

[0040] According to the results in [Fig.2], the mice in the Bifidobacterium animalis subsp. lactis SG105 group had a latency time of 67.63 ± 2.46 seconds, which is significantly longer than that of the control group (46.25 ± 1.65 seconds). The results in [Fig.2] indicate that the administration of Bifidobacterium animalis subsp. lactis SG105 can effectively improve an individual's learning ability and memory. Example 5: Active Avoidance Test

[0041] An aluminum shuttle avoidance cage of 35 (Width)^ 17 (Depth)^ 20 (Height) cm3 was divided into two compartments, between which was a guillotine door of 7.5 (Width)^ 6.5 (Depth) cm2. When the guillotine door was open, the two compartments communicated with each other. The bottom of the shuttle cage was provided with parallel metal rods arranged at 1 cm intervals and connected to a current source.

[0042] The mice in each group were tested as follows. A mouse was placed in one of the compartments and allowed to adapt to the environment for 10 seconds. Then, a conditioned stimulus (CS) consisting of light and sound was provided for 10 seconds. If the mouse subjected to the light stimulus and remained in the same compartment, an unconditioned stimulus (UCS) consisting of a 0.3 mA electric shock for five seconds was applied to the mouse once; if the mouse subjected to the light and sound stimulus entered the other compartment, no electric shock was applied. Each mouse in each group was subjected to four trials per day for four consecutive days, with each trial consisting of five UCS-UCS sessions performed at an interval of 15 to 20 minutes. The results of the active avoidance test on the second day of testing were recorded and are shown in [Fig. 3].

[0043] According to the results in [Fig. 3], the number of successful active avoidances of mice in the Bifidobacterium animalis subsp. lactis SG105 group is 12 ± 0.78, while the number of successful active avoidances of mice in the control group is 10.13 ± 0.61, which is significantly lower than that of the Bifidobacterium animalis subsp. lactis SG105 group. The results in [Fig. 3] further prove that Bifidobacterium animalis subsp. lactis SG105 can improve the loss of learning and memory ability caused by aging; in other words, the administration of Bifidobacterium animalis subsp. lactis SG105 can improve the learning and memory ability of an elderly person.

[0044] Example 6: Superoxide dismutase (SOD) activity test

[0045] 0.1 ml of liver tissue fluid was collected from each mouse in each Example 2 group, supplemented with 400 µl of ddH2O, mixed well, and allowed to stand at 4°C for 15 minutes before being centrifuged. 10 µl of the supernatant was removed, supplemented with 490 µl of sample diluent, mixed well, and then tested. The test results are shown in [Fig.4].

[0046] The results in [Fig. 4] show that after providing the sample of Bifidobacterium animalis subsp. lactis SG105 to 13-week-old SMAP8 mice, the SOD activity in the liver reached 12992 ± 231 units / g protein, which is significantly higher than the SOD activity in the liver of the control group (8735 ± 325 units / g protein). The results in [Fig. 4] indicate that Bifidobacterium animalis subsp. lactis SG105 has antioxidant activity, i.e., administration of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. lactis SG105 to an individual helps reduce oxidative stress in the individual's body to prevent oxidative damage to cells, thus producing an anti-aging effect or delaying aging-related diseases. Example 7: Catalase Activity Test (CAT)

[0047] A homogeneous liquid was obtained from the liver of each mouse in each group of Example 2 and was centrifuged at 4°C and 10000^ g for five minutes. 10 μl of the supernatant was removed and diluted 1000 times with 50 phosphate buffer. mM to produce a diluted test liquid. 2 ml of the diluted test liquid was added with 1 ml of 30 mM hydrogen peroxide and mixed well, immediately before a spectrophotometer was used to determine the change in absorbance at 240 nm and 25°C in one minute. The catalase activity in the liver of each group of mice was calculated from the corresponding changes in absorbance, and the results are shown in [Fig.5].

[0048] According to the results of [Fig.5], the concentration of CAT in the liver of mice in the Bifidobacterium animalis subsp. lactis SG105 group is 66.37 ± 2.08 nmol / min / ml, and the concentration of CAT in the liver of mice in the control group is 50.0 ± 1.35 nmol / min / ml, which is significantly lower than that of the Bifidobacterium animalis subsp. lactis SG105 group. The results indicate that Bifidobacterium animalis subsp. lactis SG105 can enhance CAT activity; in other words, administration of Bifidobacterium animalis subsp. lactis SG105 or a composition containing Bifidobacterium animalis subsp. Lactis SG105 to an individual helps prevent the individual's tissues or cells from being damaged by excessive peroxides, thus producing an antioxidant and anti-aging effect and preventing associated diseases.

Claims

Claims

1. Use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of an anti-aging and / or antioxidant composition, wherein Bifidobacterium animalis subsp. lactis SG105 has been deposited with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the deposit number being DSM 34662 and the filing date being June 8, 2023.

2. Use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of an anti-aging and / or antioxidant composition according to claim 1, the anti-aging composition being a food product, a nutritional supplement, a medicament or a body care product.

3. Use of Bifidobacterium animalis subsp. lactis SG105 according to claim 1 in the preparation of a composition for improving memory.

4. Use of Bifidobacterium animalis subsp. lactis SG105 in the preparation of a memory enhancing composition according to claim 3, wherein the memory enhancing composition is a food product, a nutritional supplement or a medicament.

5. An anti-aging and antioxidant composition, comprising an effective amount of Bifidobacterium animalis subsp. lactis SG105, wherein Bifidobacterium animalis subsp. lactis SG105 has been deposited with the German Collection of Microorganisms and Cell Cultures GmbH (Deutsche Sammlung von Mikroorganismen und Zellkulturen, or DSMZ), the deposit number being DSM 34662 and the filing date being June 8, 2023.

Images